Optimally discriminative subnetwork markers predict response to chemotherapy

Motivation: Molecular profiles of tumour samples have been widely and successfully used for classification problems. A number of algorithms have been proposed to predict classes of tumor samples based on expression profiles with relatively high performance. However, prediction of response to cancer treatment has proved to be more challenging and novel approaches with improved generalizability are still highly needed. Recent studies have clearly demonstrated the advantages of integrating protein–protein interaction (PPI) data with gene expression profiles for the development of subnetwork markers in classification problems. Results: We describe a novel network-based classification algorithm (OptDis) using color coding technique to identify optimally discriminative subnetwork markers. Focusing on PPI networks, we apply our algorithm to drug response studies: we evaluate our algorithm using published cohorts of breast cancer patients treated with combination chemotherapy. We show that our OptDis method improves over previously published subnetwork methods and provides better and more stable performance compared with other subnetwork and single gene methods. We also show that our subnetwork method produces predictive markers that are more reproducible across independent cohorts and offer valuable insight into biological processes underlying response to therapy. Availability: The implementation is available at: http://www.cs.sfu.ca/~pdao/personal/OptDis.html Contact: cenk@cs.sfu.ca; alapuk@prostatecentre.com; ccollins@prostatecentre.com

[1]  R. Bernards,et al.  Enabling personalized cancer medicine through analysis of gene-expression patterns , 2008, Nature.

[2]  Christian von Mering,et al.  STRING 8—a global view on proteins and their functional interactions in 630 organisms , 2008, Nucleic Acids Res..

[3]  Akhilesh Pandey,et al.  Human Protein Reference Database and Human Proteinpedia as discovery tools for systems biology. , 2009, Methods in molecular biology.

[4]  P. Lollini,et al.  Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  Alan Ashworth,et al.  Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance , 2006, Breast Cancer Research and Treatment.

[6]  J. Bartlett,et al.  Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge , 2010, Oncogene.

[7]  Igor Jurisica,et al.  Protein complex prediction via cost-based clustering , 2004, Bioinform..

[8]  Edward R. Dougherty,et al.  Identification of diagnostic subnetwork markers for cancer in human protein-protein interaction network , 2010, BMC Bioinformatics.

[9]  Roded Sharan,et al.  Efficient Algorithms for Detecting Signaling Pathways in Protein Interaction Networks , 2006, J. Comput. Biol..

[10]  Barbara McGrogan,et al.  Taxanes, microtubules and chemoresistant breast cancer. , 2008, Biochimica et biophysica acta.

[11]  Leming Shi,et al.  Effect of training-sample size and classification difficulty on the accuracy of genomic predictors , 2010, Breast Cancer Research.

[12]  Pierre Baldi,et al.  Assessing the accuracy of prediction algorithms for classification: an overview , 2000, Bioinform..

[13]  Tobias Müller,et al.  Identifying functional modules in protein–protein interaction networks: an integrated exact approach , 2008, ISMB.

[14]  Igor Jurisica,et al.  Inferring the functions of longevity genes with modular subnetwork biomarkers of Caenorhabditis elegans aging , 2010, Genome Biology.

[15]  Martin Ester,et al.  Inferring cancer subnetwork markers using density-constrained biclustering , 2010, Bioinform..

[16]  B. Matthews Comparison of the predicted and observed secondary structure of T4 phage lysozyme. , 1975, Biochimica et biophysica acta.

[17]  J. Ross,et al.  Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  L. Mirny,et al.  Protein complexes and functional modules in molecular networks , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[20]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[21]  Yi Huang,et al.  Estrogen Receptor α Mediates Breast Cancer Cell Resistance to Paclitaxel through Inhibition of Apoptotic Cell Death , 2007 .

[22]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  P. Johnston,et al.  5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.

[24]  K. Coombes,et al.  Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines , 2010, Breast Cancer Research and Treatment.

[25]  Salim A. Chowdhury,et al.  Identification of Coordinately Dysregulated Subnetworks in Complex Phenotypes , 2010, Pacific Symposium on Biocomputing.

[26]  R. Hardman,et al.  Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. , 1997, Cancer research.

[27]  David Cameron,et al.  A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer , 2009, Nature Medicine.

[28]  Noga Alon,et al.  Biomolecular network motif counting and discovery by color coding , 2008, ISMB.

[29]  David Cameron,et al.  Predictive signatures for chemotherapy sensitivity in breast cancer: are they ready for use in the clinic? , 2009, European journal of cancer.

[30]  Serhiy Souchelnytskyi,et al.  TGFβ1/Smad3 counteracts BRCA1-dependent repair of DNA damage , 2005, Oncogene.

[31]  Yi Huang,et al.  Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. , 2007, Cancer research.

[32]  Maria Kavallaris,et al.  Microtubules and resistance to tubulin-binding agents , 2010, Nature Reviews Cancer.

[33]  Rohit Bhargava,et al.  Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation , 2010, Modern Pathology.

[34]  Kevin C. Dorff,et al.  The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models , 2010, Nature Biotechnology.

[35]  Serhiy Souchelnytskyi,et al.  TGFbeta1/Smad3 counteracts BRCA1-dependent repair of DNA damage. , 2005, Oncogene.

[36]  T. Sørlie,et al.  Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms , 2006, BMC Genomics.

[37]  M. Kavallaris Microtubules and resistance to tubulin-binding agents , 2010, Nature Reviews. Cancer.

[38]  A Kondepudi,et al.  The expression and characterization of human recombinant proinsulin-like growth factor II and a mutant that is defective in the O-glycosylation of its E domain. , 1996, Endocrinology.

[39]  Salim A. Chowdhury,et al.  Subnetwork State Functions Define Dysregulated Subnetworks in Cancer , 2010, RECOMB.

[40]  Maqc Consortium The MicroArray Quality Control ( MAQC )-II study of common practices for the development and validation of microarray-based predictive models , 2012 .

[41]  T. Ideker,et al.  Network-based classification of breast cancer metastasis , 2007, Molecular systems biology.

[42]  Richard M. Karp,et al.  Detecting Disease-Specific Dysregulated Pathways Via Analysis of Clinical Expression Profiles , 2008, RECOMB.

[43]  R. Sainson,et al.  A Conserved Mechanism for Steroid Receptor Translocation to the Plasma Membrane* , 2007, Journal of Biological Chemistry.

[44]  Xing-Ming Zhao,et al.  A systems biology approach to identify effective cocktail drugs , 2010, BMC Systems Biology.

[45]  Martin Ester,et al.  Quantifying Systemic Evolutionary Changes by Color Coding Confidence-Scored PPI Networks , 2009, WABI.

[46]  D. Yee,et al.  Insulin‐like growth factor (IGF)‐I rescues breast cancer cells from chemotherapy‐induced cell death – proliferative and anti‐apoptotic effects , 1999, Breast Cancer Research and Treatment.

[47]  Roded Sharan,et al.  Topology-Free Querying of Protein Interaction Networks , 2009, RECOMB.

[48]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[49]  Noga Alon,et al.  Color-coding , 1995, JACM.

[50]  F. Shibasaki,et al.  Dissociation of Bax from a Bcl-2/Bax heterodimer triggered by phosphorylation of serine 70 of Bcl-2. , 2001, Journal of biochemistry.

[51]  Roded Sharan,et al.  QNet: A Tool for Querying Protein Interaction Networks , 2007, RECOMB.

[52]  Jae K. Lee,et al.  A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery , 2007, Proceedings of the National Academy of Sciences.

[53]  L. Ein-Dor,et al.  Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[54]  X-S Zhang,et al.  Identifying differentially expressed pathways via a mixed integer linear programming model. , 2009, IET systems biology.

[55]  Roded Sharan,et al.  QPath: a method for querying pathways in a protein-protein interaction network , 2006, BMC Bioinformatics.